227 related articles for article (PubMed ID: 30980447)
1. Seasonality of i.v. immunoglobulin responsiveness in Kawasaki disease.
Kido S; Ae R; Kosami K; Matsubara Y; Makino N; Sasahara T; Kuwabara M; Aoyama Y; Yashiro M; Yanagawa H; Nakamura Y
Pediatr Int; 2019 Jun; 61(6):539-543. PubMed ID: 30980447
[TBL] [Abstract][Full Text] [Related]
2. Seasonality in clinical courses of Kawasaki disease.
Shimizu D; Hoshina T; Kawamura M; Tomita Y; Hidaka Y; Kojiro M; Muneuchi J; Kamizono J; Yamaguchi K; Fujino Y; Kusuhara K
Arch Dis Child; 2019 Jul; 104(7):694-696. PubMed ID: 30413486
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study.
Miyata K; Kaneko T; Morikawa Y; Sakakibara H; Matsushima T; Misawa M; Takahashi T; Nakazawa M; Tamame T; Tsuchihashi T; Yamashita Y; Obonai T; Chiga M; Hori N; Komiyama O; Yamagishi H; Miura M;
Lancet Child Adolesc Health; 2018 Dec; 2(12):855-862. PubMed ID: 30337183
[TBL] [Abstract][Full Text] [Related]
4. Importance of C-reactive protein level in predicting non-response to additional intravenous immunoglobulin treatment in children with Kawasaki disease: a retrospective study.
Iwashima S; Kimura M; Ishikawa T; Ohzeki T
Clin Drug Investig; 2011; 31(3):191-9. PubMed ID: 21456105
[TBL] [Abstract][Full Text] [Related]
5. The time option of IVIG treatment is associated with therapeutic responsiveness and coronary artery abnormalities but not with clinical classification in the acute episode of Kawasaki disease.
Samadli S; Liu FF; Mammadov G; Wang JJ; Liu HH; Wu YF; Luo HH; Wu Y; Chen WX; Zhang DD; Wei W; Hu P
Pediatr Rheumatol Online J; 2019 Jul; 17(1):53. PubMed ID: 31366406
[TBL] [Abstract][Full Text] [Related]
6. Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan.
Uehara R; Belay ED; Maddox RA; Holman RC; Nakamura Y; Yashiro M; Oki I; Ogino H; Schonberger LB; Yanagawa H
Pediatr Infect Dis J; 2008 Feb; 27(2):155-60. PubMed ID: 18174868
[TBL] [Abstract][Full Text] [Related]
7. Fever pattern and C-reactive protein predict response to rescue therapy in Kawasaki disease.
Nakagama Y; Inuzuka R; Hayashi T; Shindo T; Hirata Y; Shimizu N; Inatomi J; Yokoyama Y; Namai Y; Oda Y; Takamizawa M; Harita Y; Oka A
Pediatr Int; 2016 Mar; 58(3):180-184. PubMed ID: 26222760
[TBL] [Abstract][Full Text] [Related]
8. Low risk of treatment resistance in Down syndrome with Kawasaki disease.
Takatsuki S; Ogata S; Ishii M; Yokozawa M; Ono M; Fujiwara M; Ida H; Motomura H; Moriuchi H; Taketazu M; Kawamura Y; Kawano T; Izumi T; Shiono J; Tsuchiya S; Tsuchiya K; Goushi T; Ichida F; Saji T
Pediatr Int; 2017 Dec; 59(12):1236-1239. PubMed ID: 28960680
[TBL] [Abstract][Full Text] [Related]
9. Delayed intravenous immunoglobulin treatment increased the risk of coronary artery lesions in children with Kawasaki disease at different status.
Qiu H; He Y; Rong X; Ren Y; Pan L; Chu M; Wu R; Shi H
Postgrad Med; 2018 May; 130(4):442-447. PubMed ID: 29745742
[TBL] [Abstract][Full Text] [Related]
10. Prediction of intravenous immunoglobulin resistance in patients with Kawasaki disease according to the duration of illness prior to treatment.
Ha KS; Lee J; Lee KC
Eur J Pediatr; 2020 Feb; 179(2):257-264. PubMed ID: 31713683
[TBL] [Abstract][Full Text] [Related]
11. The effects of early intravenous immunoglobulin therapy for Kawasaki disease: The 22nd nationwide survey in Japan.
Kuwabara M; Yashiro M; Ae R; Yanagawa H; Nakamura Y
Int J Cardiol; 2018 Oct; 269():334-338. PubMed ID: 30049499
[TBL] [Abstract][Full Text] [Related]
12. Sivelestat sodium hydrate treatment for refractory Kawasaki disease.
Ebata R; Yasukawa K; Nagai K; Saito Y; Higashi K; Homma J; Takada N; Takechi F; Saito N; Kobayashi H; Okunushi K; Hamada H; Kohno Y; Hanaoka H; Shimojo N
Pediatr Int; 2019 May; 61(5):438-443. PubMed ID: 30916859
[TBL] [Abstract][Full Text] [Related]
13. Variability in Response to Intravenous Immunoglobulin in the Treatment of Kawasaki Disease.
Downie ML; Manlhiot C; Latino GA; Collins TH; Chahal N; Yeung RS; McCrindle BW
J Pediatr; 2016 Dec; 179():124-130.e1. PubMed ID: 27659027
[TBL] [Abstract][Full Text] [Related]
14. Intravenous immunoglobulin treatment responsiveness depends on the degree of CD8+ T cell activation in Kawasaki disease.
Ye Q; Gong FQ; Shang SQ; Hu J
Clin Immunol; 2016 Oct; 171():25-31. PubMed ID: 27519954
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of albumin for intravenous immunoglobulin resistance in a large cohort of Kawasaki disease patients.
Zhang R; Shuai S; Zhang H; Cai J; Cui N; Tang M; Xing S; Gao Y; Liu X; Yang X
Ital J Pediatr; 2023 Jun; 49(1):78. PubMed ID: 37357258
[TBL] [Abstract][Full Text] [Related]
16. Analysis of Age, Sex, Lack of Response to Intravenous Immunoglobulin, and Development of Coronary Artery Abnormalities in Children With Kawasaki Disease in Japan.
Takekoshi N; Kitano N; Takeuchi T; Suenaga T; Kakimoto N; Suzuki T; Kada TT; Shibuta S; Tachibana S; Murayama Y; Yamaga H; Suzuki H
JAMA Netw Open; 2022 Jun; 5(6):e2216642. PubMed ID: 35696166
[TBL] [Abstract][Full Text] [Related]
17. Clarithromycin Plus Intravenous Immunoglobulin Therapy Can Reduce the Relapse Rate of Kawasaki Disease: A Phase 2, Open-Label, Randomized Control Study.
Nanishi E; Nishio H; Takada H; Yamamura K; Fukazawa M; Furuno K; Mizuno Y; Saigo K; Kadoya R; Ohbuchi N; Onoe Y; Yamashita H; Nakayama H; Hara T; Ohno T; Takahashi Y; Hatae K; Harada T; Shimose T; Kishimoto J; Ohga S; Hara T
J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28684643
[TBL] [Abstract][Full Text] [Related]
18. A low-frequency IL4R locus variant in Japanese patients with intravenous immunoglobulin therapy-unresponsive Kawasaki disease.
Amano Y; Akazawa Y; Yasuda J; Yoshino K; Kojima K; Kobayashi N; Matsuzaki S; Nagasaki M; Kawai Y; Minegishi N; Ishida N; Motoki N; Hachiya A; Nakazawa Y; Yamamoto M; Koike K; Takeshita T
Pediatr Rheumatol Online J; 2019 Jul; 17(1):34. PubMed ID: 31269967
[TBL] [Abstract][Full Text] [Related]
19. Effect of i.v. immunoglobulin in the first 4 days of illness in Kawasaki disease.
Shiozawa Y; Inuzuka R; Shindo T; Mafune R; Hayashi T; Hirata Y; Shimizu N; Inatomi J; Yokoyama Y; Namai Y; Oda Y; Takamizawa M; Harita Y; Kawahara T; Oka A
Pediatr Int; 2018 Apr; 60(4):334-341. PubMed ID: 29292568
[TBL] [Abstract][Full Text] [Related]
20. Relationship between post-IVIG IgG levels and clinical outcomes in Kawasaki disease patients: new insight into the mechanism of action of IVIG.
Goto R; Inuzuka R; Shindo T; Namai Y; Oda Y; Harita Y; Oka A
Clin Rheumatol; 2020 Dec; 39(12):3747-3755. PubMed ID: 32458247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
